"Arlington Dermatology offers medical and cosmetic treatments for a wide variety of skin conditions. We are led by Dr. Michael Bukhalo, a board certified and national recognized dermatologist. We treat skin cancer, psoriasis, rosacea, acne, and much more. Call today to schedule an appointment."

During the past decade, Arlington Dermatology conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 21 clinical trials were completed, i.e. on average, 77.8% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 20 clinical trials were completed. i.e. 222.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Arlington Dermatology" #1 sponsor was "Eli Lilly and Company" with 10 trials, followed by "Janssen Research & Development, LLC" with 6 trials sponsored, "Cassiopea SpA" with 2 trials sponsored, "Dermira, Inc." with 2 trials sponsored and "LEO Pharma" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Arlington Dermatology" #1 collaborator was "Dermira, Inc." with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator and "Athenex, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Arlington Dermatology" are "Atopic Dermatitis" (7 trials), "Psoriasis" (7 trials), "Acne Vulgaris" (5 trials), "Plaque Psoriasis" (4 trials) and "Psoriasis Vulgaris" (2 trials). Many other conditions were trialed in "Arlington Dermatology" in a lesser frequency.

Most popular intervention types in "Arlington Dermatology" are "Drug" (27 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Guselkumab" (4 trials), "Mirikizumab" (3 trials), "Baricitinib" (2 trials) and "CB-03-01 cream, 1%" (2 trials). Other intervention names were less common.

The vast majority of trials in "Arlington Dermatology" are 30 trials for "All" genders.

Currently, there are NaN active trials in "Arlington Dermatology". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Arlington Dermatology, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Arlington Dermatology, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".